靶点- |
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
100 项与 GMP Endotherapeutics Inc 相关的临床结果
0 项与 GMP Endotherapeutics Inc 相关的专利(医药)
100 项与 GMP Endotherapeutics Inc 相关的药物交易
100 项与 GMP Endotherapeutics Inc 相关的转化医学